TPD52 and prostate carcinoma: In summary, our findings provide new insight into the role of PC-1/PrLZ for promoting DNA DSB repair and inhibiting IR-induced autophagic cell death and suggest that PC-1/PrLZ may be a novel radio-therapeutic target for treating advanced prostate cancer.